CombinatoRx to Webcast Conference Call Discussing Fourth Quarter and Year End 2009 Financial Results
2010年3月18日 - 9:30PM
ビジネスワイヤ(英語)
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it
will report financial results for the fourth quarter and year end
2009 before market opens on Thursday, March 25, 2010 followed by a
conference call at 8:30 a.m. ET in which senior management will
provide an update on the company, discuss fourth quarter and year
end 2009 financial results and discuss expectations for the
future.
To access the call, please dial 866-383-7998 (domestic) or
617-597-5329 (international) five minutes prior to the start time
and provide the passcode 67986161. A replay of the call will be
available beginning at 11:30 a.m. ET on March 25, 2010. To access
the replay, please dial 888-286-8010 (domestic) or 617-801-6888
(international), and provide the passcode 35427451.
A live audio webcast of the call will also be available on the
“Investors” section of the company’s website, www.combinatorx.com.
An archived audio webcast will be available on the CombinatoRx
website two hours after the event.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates
with a focus on the treatment of pain and inflammation. The company
applies its combination drug discovery capabilities and its
selective ion-channel modulation platform to generate innovative
therapeutics. To learn more about CombinatoRx, please visit
www.combinatorx.com.
Forward-Looking Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
concerning CombinatoRx, the CombinatoRx drug discovery
technologies, and the business plans of CombinatoRx. These
forward-looking statements about future expectations, plans,
objectives and prospects of CombinatoRx may be identified by words
like "believe," "expect," "may," "will," "should," "seek," or
“could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the
unproven nature of the CombinatoRx drug discovery technologies, the
Company's ability to obtain additional financing or funding for its
research and development and those other risks that can be found in
the "Risk Factors" section beginning on page 31 of CombinatoRx's
Form S-4 Registration Statement filed in connection with its merger
with Neuromed (File No. 333-161146), on file with the Securities
and Exchange Commission and the other reports that CombinatoRx
periodically files with the Securities and Exchange Commission.
Actual results may differ materially from those CombinatoRx
contemplated by these forward-looking statements. These forward
looking statements reflect management’s current views and
CombinatoRx does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
(c) 2010 CombinatoRx, Incorporated. All rights reserved.
Combinatorx (NASDAQ:CRXX)
過去 株価チャート
から 5 2024 まで 6 2024
Combinatorx (NASDAQ:CRXX)
過去 株価チャート
から 6 2023 まで 6 2024